跳至主要内容
临床试验/NCT01190631
NCT01190631已完成不适用

An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation After SN60WF IOL Implantation

Alcon Research2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2010年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
2
主要终点
Contrast Sensitivity

研究概览

简要总结

The purpose of this study was to evaluate total residual spherical aberration (TSA) post-IOL implantation, and to determine if an association exists between TSA, postoperative high order aberrations (HOA), and functional vision following IOL implantation in patients grouped by pre-operative corneal spherical aberration (CSA).

详细描述

Patients will be grouped by pre-operative corneal spherical aberration (CSA) measures, i.e., ≤0.230 micron and ≥0.270 micron.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age-related cataract grade 3 or lower in at least one eye;
  • Planned cataract removal via phacoemulsification with an implantation of an aspheric IOL;
  • Able to have an operation within 30 days of preoperative evaluation;
  • Good ocular health, with the exception of cataracts;
  • ≤ 1.50 diopter (D) of preoperative astigmatism by keratometry;
  • Willing and able to understand and sign an informed consent;
  • Willing and able to attend postoperative examinations per protocol schedule;
  • Able to achieve 6.5mm dilated pupil;
  • Other protocol-defined inclusion criteria may apply.

排除标准

  • Preoperative ocular pathology as specified in protocol;
  • Preoperative corneal pathology as specified in protocol;
  • Keratometric astigmatism exceeding 1.50 diopter;
  • Planned postoperative refraction for mono-vision;
  • Uncontrolled diabetes;
  • Use of any systemic or topical drug known to interfere with visual performance;
  • Contact lens use during the active treatment portion of the trial;
  • Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis;
  • Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or study device implantation or may interfere with the interpretation of study results;
  • Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial;
  • Intraocular conventional surgery within the past three months or intraocular laser surgery within one month in the operated eye;
  • Pregnant or nursing mothers and females of childbearing potential not practicing a reliable and medically acceptable method of birth control;
  • Other protocol-defined exclusion criteria may apply.

结局指标

主要结局

Contrast Sensitivity

时间窗: Day 90 postoperative

Contrast sensitivity is the measurement of one's ability to detect slight changes in luminance before it becomes indistinguishable. It is measured in logarithmic units by means of an illuminated box, the CSV 1000 by Vector Vision. A higher value for the logarithmic units translates to better contrast sensitivity.

次要结局

  • Total Higher Order Aberrations(Day 90 postoperative)
  • Corneal Spherical Aberration(Day 90 postoperative)
  • Uncorrected Visual Acuity (UCVA)(Day 90 postoperative)
  • Best Corrected Visual Acuity (BCVA)(Day 90 postoperative)
  • Low Contrast (10%) Visual Acuity(Day 90 postoperative)
  • Quality of Vision Questionnaire(Day 90 postoperative)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验